Miami, United States
OpenEvidence, founded in 2021, stands as a trailblazer in the AI and SaaS industries, headquartered in the United States. Committed to "Organizing and expanding the world’s medical knowledge and making it more useful," this company is driving significant change in the medical information space. Having launched during the Mayo Clinic Platform Accelerate program, OpenEvidence has quickly established itself as a leader, recognized as a Content Partner by the prestigious New England Journal of Medicine.
The company’s recent financial traction was bolstered by a $210.00M Series B Extension funding round on 01 July 2025. This investment round was supported by a consortium of high-profile investors including Kleiner Perkins, Coatue, Greycroft, GV, Thrive Capital, Conviction, and Sequoia. Investors are drawn to OpenEvidence’s innovative approach and market influence, underpinned by backing from Sequoia and strategic partnerships that amplify its leading status.
